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Stimulation of serum-starved human embryonic kid-
ney (HEK) 293 cells with either the phorbol ester, 12-O-
tetradecanoylphorbol-13-acetate (TPA), or insulin re-
sulted in increases in the phosphorylation of 4E-BP1
and p70 S6 kinase, eIF4F assembly, and protein synthe-
sis. All these effects were blocked by rapamycin, a spe-
cific inhibitor of mTOR. Phosphatidylinositol 3-kinase
and protein kinase B were activated by insulin but not
by TPA. Therefore TPA can induce eIF4F assembly, pro-
tein synthesis, and the phosphorylation of p70 S6 kinase
and 4E-BP1 independently of both phosphatidylinositol
3-kinase and protein kinase B. Using two structurally
unrelated inhibitors of MEK (PD098059 and U0126), we
provide evidence that Erk activation is important in
TPA stimulation of eIF4F assembly and the phosphoryl-
ation of p70 S6 kinase and 4E-BP1 and that basal MEK
activity is important for basal, insulin, and TPA-stimu-
lated protein synthesis. Transient transfection of consti-
tutively active mitogen-activated protein kinase inter-
acting kinase 1 (the eIF4E kinase) indicated that
inhibition of protein synthesis and eIF4F assembly by
PD098059 is not through inhibition of eIF4E phospho-
rylation but of other signals emanating from MEK. This
report also provides evidence that increased eIF4E
phosphorylation alone does not affect the assembly of
the eIF4F complex or general protein synthesis.
Protein synthesis is regulated by a variety of stimuli includ-
ing insulin (1) and phorbol esters (2–6). A key step in the
regulation of protein synthesis is the assembly of the initiation
complex eIF4F,1 containing the initiation factors eIF4G, a large
scaffolding protein, eIF4E, the protein which binds to the 59 cap
structure (7-methylguanosine triphosphate) and eIF4A, a bidi-
rectional RNA helicase (reviewed by Sonenberg (7)). The for-
mation of the eIF4F complex (usually defined operationally as
the association of eIF4G with eIF4E) is regulated by a variety
of stimuli through multiple phosphorylation events. Two prin-
cipal mechanisms have been suggested to play an important
role in regulating eIF4F assembly. First, it has been proposed
that the phosphorylation of eIF4E may be important in the
formation of the eIF4F complex, as eIF4E associated with
eIF4G is more highly phosphorylated than free eIF4E (8, 9) and
since increased phosphorylation of eIF4E often parallels in-
creases in total protein synthesis (reviewed by Kleijn et al.
(10)). Recent data have provided evidence that eIF4E is phos-
phorylated by MAP kinase interacting kinase 1 (Mnk1), which
is itself phosphorylated by both p38-MAPK and Erk (11–15).
The second mechanism regulating eIF4F assembly involves a
family of eIF4E-binding proteins (4E-BPs, archetype 4E-BP1)
whose affinity for eIF4E is regulated through their phospho-
rylation (16–20). 4E-BP1 binds to a site on eIF4E which over-
laps the binding site for eIF4G (18, 21, 22). 4E-BP1 thus com-
petes with eIF4G for binding to eIF4E and can therefore inhibit
eIF4F complex formation. Phosphorylation of 4E-BP1 leads to
a reduction in its affinity for eIF4E and its dissociation, making
eIF4E available to bind eIF4G, potentially leading to an in-
crease in mRNA translation (18–20).
Most studies on the signaling pathways involved in the reg-
ulation of protein synthesis have focused on insulin (reviewed
by Proud and Denton (1)). It has been demonstrated that insu-
lin can lead to increased eIF4F assembly, activation of protein
synthesis, and the phosphorylation of 4E-BP1. Insulin also
induces the phosphorylation of p70 S6 kinase which phospho-
rylates ribosomal protein S6 and is linked to an increase in the
translation of a specific subset of mRNAs which contain poly-
pyrimidine tracts within their 59-untranslated regions (59-ter-
minal oligopyrimidine tract mRNAs) (23–25). Phosphorylation
of 4E-BP1 and p70 S6 kinase in response to insulin is inhibited
both by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibi-
tors wortmannin and LY294002 (26–30) and by the inhibitor of
mTOR, rapamycin, indicating that PI 3-kinase and mTOR play
a role in their regulation (19, 31–34). PKB, a kinase which lies
downstream of PI 3-kinase and is activated by phosphorylation
by PDK1 and 2 in response to insulin (35), is thought to be
important in the signal transduction pathway which leads to
the phosphorylation of both p70 S6 kinase and 4E-BP1 (27, 36).
It has been demonstrated that phorbol esters can also lead to
increases in protein synthesis and the phosphorylation status
of a number of initiation factors, including members of the
eIF4F complex (2–6). However, the roles of these phosphoryl-
ation events in the activation of protein synthesis by phorbol
ester and the nature of the signaling pathways which lead to
these increases are unknown. Phorbol esters offer a paradigm
for stimuli acting via phospholipase C which generate diacylg-
lycerol (37) and therefore use a proximal signaling pathway
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which may be different to that utilized by insulin.
In this report we characterize in parallel the signaling path-
ways by which both insulin and phorbol esters increase eIF4F
assembly and total protein synthesis in HEK 293 cells. We
demonstrate that the phorbol ester, TPA, and insulin stimulate
eIF4F assembly and protein synthesis. The stimulation of
eIF4F assembly and protein synthesis by insulin and TPA is
inhibited by rapamycin. However, TPA stimulates eIF4F as-
sembly and protein synthesis through a mechanism that is
independent of PI 3-kinase and PKB but dependent on Erk,
whereas insulin stimulates the eIF4F assembly and protein
synthesis through a mechanism that requires PI 3-kinase and
may involve PKB. We also demonstrate that increased eIF4E
phosphorylation is not required for stimulation of eIF4F assem-
bly. The signaling pathways and the roles of individual initia-
tion factors in eIF4F assembly and protein synthesis are
discussed.
EXPERIMENTAL PROCEDURES
Chemicals and Materials—[35S]Methionine and [g-32P]ATP were
purchased from Amersham Pharmacia Biotech. Microcystin, wortman-
nin, rapamycin, PD098059 and CHAPS were from Calbiochem. Mate-
rials for tissue culture were from Life Technologies, Inc. m7GTP-Sepha-
rose was from Amersham Pharmacia Biotech. U0126 was obtained from
Promega. All other chemicals (unless stated) were obtained from Sigma.
Cell Culture and Treatment of Cells—HEK 293 cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies,
Inc.) supplemented with 10% fetal calf serum. Prior to treatment, cells
were grown to 80% confluence before being serum starved for 16 h.
Details of treatments are provided in the figure legends. After treat-
ment, cells were washed in phosphate-buffered saline and lysed in
extraction buffer (0.1% Triton X-100, 50 mM b-glycerophosphate, pH
7.4, 1.5 mM EGTA, 1 mM benzamidine-HCl, 0.5 mM sodium orthovana-
date, 0.1 mM phenylmethylsulfonyl fluoride, 1 mg/ml each of pepstatin
A, antipain, and leupeptin). The lysates were then centrifuged for 10
min at 16,000 3 g. The supernatants were removed and used for further
analysis.
SDS-Polyacrylamide Gel Electrophoresis (PAGE), Isoelectric Focus-
ing, and Immunoblotting—SDS-PAGE and Western blotting were per-
formed as described previously (38, 39). Anti-human eIF4E antiserum
was raised against a synthetic peptide corresponding to residues 5–23
of the protein. The anti-4E-BP1 antibody was raised against a peptide
corresponding to residues 101–113 of human 4E-BP1. Anti-eIF4G1 and
-eIF4A were generous gifts from Drs S. Morley (University of Sussex)
and H. Trachsel (Bern University), respectively. Anti-phospho-PKB
Ser473 and anti-phospho-Erk antibodies were supplied by New England
Biolabs. Isoelectric focusing of eIF4E was performed as described pre-
viously (6) using Ampholines (Amersham Pharmacia Biotech) in the pH
range 3.5–10.
m7GTP-Sepharose Chromatography—m7GTP-Sepharose chromatog-
raphy was performed as described previously (6). 25 ml of a 50/50 slurry
of m7GTP-Sepharose CL-6B (Amersham Pharmacia Biotech) was added
to 0.2–0.5 mg of protein. The lysates were then rotated for 1 h at 4 °C.
The m7GTP-Sepharose was pelleted by centrifugation at 1000 3 g for 2
min. The beads were then washed three times in extraction buffer. For
SDS-PAGE, proteins were removed from the m7GTP matrix by boiling
it in SDS loading buffer.
In Vitro Kinase Assays—PKB assays were performed as described by
Cross et al. (40). Briefly, lysates were subjected to immunoprecipitation
with antibodies directed against PKB a, b, and g (a generous gift from
Dr. D. Alessi, Dundee University). The immunoprecipitates were incu-
bated with kinase buffer (50 mM Tris, pH 7.4, 5 mM protein kinase A
inhibitor, 100 mM EGTA, 10 mM Mg(Ac)2, 1 mM microcystin, 50 mM ATP,
1 mCi of [g-32P]ATP) and 30 mM of the peptide substrate “Crosstide,”
(GRPRTSSFAEG) at 30 °C for 15 min. The kinase reactions were then
spotted onto DE81 paper, washed with 1% phosphoric acid, and radio-
activity was determined by the Cerenkov method. For in vitro PI 3-ki-
nase assays, cell lysates (;0.5 mg of protein) were mixed with anti-
phosphotyrosine (clone PY20, generously given by Drs. A. N. Carter, J.
Miesenhelder and S. Simon, The MBVL, Salk Institute, La Jolla, CA).
Immunoprecipitates were collected by brief centrifugation and washed
twice with 1 ml each of: (i) 25 mM Hepes, 120 mM NaCl, 5 mM b-glyc-
erophosphate, 1 mM MgCl2, 1 mM EGTA, 0.2 mM EDTA, 50 mM sodium
fluoride, 1%(v/v) Triton X-100, pH 7.6; (ii) as i without Triton X-100 to
remove detergent; (iii) 100 mM Tris, 500 mM LiCl, pH 8.0; (iv) 25 mM
Hepes, 120 mM NaCl, 5 mM b-glycerophosphate, 2.5 mM MgCl2, 1 mM
EGTA, 0.2 mM EDTA, pH 7.6, to remove high salt, each wash was
supplemented with 1 mM Na3VO4, 1 mM dithiothreitol, 0.1 mM phenyl-
methylsulfonyl fluoride, 0.1 mM benzamidine, and 0.02 mM leupeptin.
The detergent and high salt washes were to remove possible contami-
nants. The washed beads were re-suspended in 0.04 ml of the final
buffer additionally supplemented with 0.01 mM [g-32P]ATP (10–25 Ci/
mmol) and phosphatidylinositol/phosphatidylserine vesicles to give fi-
nal concentrations of 0.1 mM with respect to each lipid. Vesicles were
prepared as a 4-fold concentrate by sonicating dried phospholipid films
in 25 mM Hepes, 100 mM NaCl, 1 mM EGTA, pH 7.6, using 3 3 20-s
bursts at approximately 50% maximum power from a probe tip
equipped with a micro-cup horn. Kinase reactions were stopped by
addition of 0.6 ml of methanol, chloroform, 12 M HCl (80:40:1, v:v)
followed by 0.2 ml of chloroform and 0.12 ml of 0.1 M HCl. Samples were
mixed and briefly spun and the lower phases removed to fresh tubes
and washed with 0.78 ml of synthetic upper phase. The washed lower
phases were dried in vacuum, re-suspended in 0.02 ml of chloroform/
methanol (2:1, v/v) and [32P]PtdIns(3)P present separated from contam-
inating materials by thin layer chromatography (TLC) on Silica Gel 60
plates, pre-dipped in 1% (w/v) potassium oxalate, 5 mM EDTA, pH 8.5
(in methanol:water, 1:1 v/v), and dried prior to use, developed in meth-
anol, chloroform, water, 35% ammonia solution (20:15:5:3, v/v). Bands
corresponding to [32P]phosphatidylinositol 3-phosphate were located by
autoradiography.
Protein Synthesis Measurements—15 min after stimulation with ei-
ther insulin or TPA the cells were incubated with [35S]methionine at 10
mCi/ml for 30 min. The cells were then washed in phosphate-buffered
saline and lysed in extraction buffer. 20 mg of protein was spotted onto
3MM paper (Whatman). The filters were then washed by boiling them
for 1 min in 10% trichloroacetic acid containing 0.1 g/liter methionine.
This was repeated three times. The filters were then dried and im-
mersed in scintillant before determining radioactivity by scintillation
counting.
32P in Vivo Labeling—Cells were serum starved in Dulbecco’s mod-
FIG. 1. Insulin and TPA stimulate
eIF4F assembly concomitantly with
increased phosphorylation of 4E-BP1
and p70 S6 kinase. HEK 293 cells were
serum starved for 16 h prior to the addition
of either 1 mM TPA or 100 nM insulin for the
time periods indicated. a, analysis of pro-
teins isolated by m7GTP-Sepharose pull-
down separated on a SDS-polyacrylamide
gel followed by Western blotting using an-
tisera against eIF4E, eIF4G1, eIF4A, and
4E-BP1. b, 20 mg of cell lysates were run on
a SDS-polyacrylamide gel followed by
Western blotting using anti-4E-BP1 anti-
serum. Phospho-4E-BP1 represents the
more phosphorylated forms of 4E-BP1. c,
10 mg of cell lysates were run on a SDS-
polyacrylamide gel followed by Western
blotting using anti-p70 S6 kinase anti-
serum. These results are representative of
three separate experiments.
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ified Eagle’s medium minus phosphate medium for 16 h prior to addi-
tion of 50 mCi/ml [32P]orthophosphate. Cells were then treated with
inhibitors or agonists as indicated in the text.
Transient Transfections—Transient transfections were performed as
described by Alessi et al. (41). Plasmid pEBG-T332D expressing consti-
tutively active Mnk1 (Mnk1 T332D) were kindly provided by Dr. A. J.
Waskiewicz (Fred Hutchinson Cancer Center, Seattle, WA) (12, 15).
RESULTS
Insulin and TPA Increase eIF4F Assembly and Protein Syn-
thesis—Serum-starved HEK 293 cells were treated with either
TPA or insulin and samples were taken over a 40-min time
course. eIF4F assembly and the phosphorylation of 4E-BP1 and
p70 S6 kinase were monitored over this time period. TPA and
insulin each increased the assembly of the eIF4F complex, as
characterized by an increase in the association of eIF4G and
eIF4A with eIF4E (Fig. 1a) concomitantly with the dissociation
of 4E-BP1 from eIF4E. These effects occurred in parallel with
the phosphorylation of 4E-BP1 and p70 S6 kinase as indicated
by shifts in their migrations on SDS-PAGE (Fig. 1, b and c).
However, differences were observed in the time taken to reach
maximal p70 S6 kinase phosphorylation, 4E-BP1 phosphoryl-
ation, and eIF4F assembly for the two stimuli, with insulin
treatment resulting in a maximal effect within 15–20 min as
compared with 30–40 min in response to TPA (the response to
TPA does not significantly increase from 40 to 60 min (data not
shown)). Stimulation with either insulin or TPA does not al-
ways result in the complete dissociation of 4E-BP1 (Fig. 1a)
indicating maximal stimulation has not been reached. How-
ever, the response to TPA levels out by approximately 40 min
as little additional stimulation was observed by 60 min (results
not shown). The apparent association of eIF4A with eIF4E in
the absence of eIF4G seen in Fig. 1a is due to the greater
sensitivity of the anti-eIF4A antibody as compared with that of
the anti-eIF4G1 antibody, and reflects a low basal level of
eIF4F complexes in untreated cells.
Measurements of the incorporation of [35S]methionine into
protein revealed that insulin or TPA treatment of the cells each
induced a substantial increase in protein synthesis of approx-
imately 40–50% over untreated cells (see Figs. 2d and 3e).
Taken together, these data show that treatment of HEK 293
cells with TPA or insulin leads to the phosphorylation of p70 S6
kinase and 4E-BP1 in parallel with increases in eIF4F assem-
bly and the rate of total protein synthesis.
Stimulation by TPA and Insulin of eIF4F Assembly and
Protein Synthesis Is Dependent upon mTOR—mTOR plays an
important role in the regulation of the phosphorylation of both
p70 S6 kinase and 4E-BP1 in response to many stimuli (32–34),
although the signal transduction pathways leading to the ac-
tivation of mTOR are essentially unknown. We therefore in-
vestigated the role of mTOR in TPA- or insulin- stimulated
eIF4F assembly, protein synthesis, and 4E-BP1 and p70 S6
kinase phosphorylation using a specific inhibitor of mTOR,
rapamycin. Cells were incubated with rapamycin for 45 min
prior to treatment with insulin or TPA. Rapamycin blocked the
stimulation of eIF4F assembly by either insulin or TPA and
also inhibited the phosphorylation of p70 S6 kinase and 4E-
BP1 (Fig. 2, a-c). The stimulation of protein synthesis by insu-
lin or TPA was also partially inhibited by rapamycin when
compared with rapamycin-treated control cells (Fig. 2d). The
data show that mTOR plays a central role in the stimulation of
eIF4F assembly and the phosphorylation of 4E-BP1 and p70 S6
kinase in response to TPA or insulin.
Stimulation by Insulin, but Not TPA, of eIF4F Assembly and
Protein Synthesis Is Dependent on the Activation of PI 3-Ki-
nase—It has previously been shown, in several cell types, that
the activation of both p70 S6 kinase and 4E-BP1 by insulin
occurs by a mechanism involving PI 3-kinase (see e.g. Refs. 36
and 42). We therefore wished to determine whether TPA and
insulin activated PI 3-kinase in HEK 293 cells.
Antibodies directed against phosphotyrosine were used to
pull-down phosphotyrosine-associated PI 3-kinase from insulin
or TPA-treated cell lysates. The activity of PI 3-kinase was
then determined by an in vitro assay (Fig. 3a). Insulin treat-
ment led to a large increase in PI 3-kinase activity as indicated
by the generation of phosphatidylinositol 3-phosphate (Fig. 3a).
TPA did not activate PI 3-kinase at any of the time points
tested (Fig. 3a). However, TPA might activate PI 3-kinase via a
phosphotyrosine independent mechanism. Therefore, in order
to investigate further the possible role of PI 3-kinase in insulin
and TPA-stimulated eIF4F assembly, protein synthesis and the
phosphorylation of both p70 S6 kinase and 4E-BP1, serum-
starved cells were pretreated with wortmannin, an inhibitor of
PI 3-kinase, before addition of either insulin or TPA. As shown
in Fig. 1, TPA and insulin increased eIF4F assembly (Fig. 3b)
and the phosphorylation of p70 S6 kinase and 4E-BP1 (Fig. 3,
c and d), as well as protein synthesis (Fig. 3e). In the presence
FIG. 2. The mTOR inhibitor rapamycin inhibits TPA or insu-
lin-stimulated eIF4F assembly and protein synthesis. HEK 293
cells were serum starved for 16 h. Cells were pretreated with 200 nM
rapamycin (RAP) for 40 min prior to the addition of 1 mM TPA or 100 nM
insulin for 45 min. a, analysis of proteins isolated by m7GTP-Sepharose
pull-down separated on a SDS-polyacrylamide gel followed by Western
blotting using antisera against eIF4E, eIF4G1, and 4E-BP1. b, 10 mg of
cell lysates were run on a SDS-polyacrylamide gel followed by Western
blotting using anti p70 S6 kinase antiserum. c, 20 mg of cell lysates were
run on a SDS-polyacrylamide gel followed by Western blotting using
anti-4E-BP1 antiserum. Phospho-4E-BP1 represents the more phos-
phorylated forms of 4E-BP1. d, incorporation of [35S]methionine into
protein expressed as % of control (n 5 4: 6S.E.). These results are
representative of three separate experiments, except where stated.
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of wortmannin, insulin was unable to stimulate eIF4F assem-
bly, the phosphorylation of p70 S6 kinase and 4E-BP1 or pro-
tein synthesis (Fig. 3, b-e). However, the stimulation by TPA of
eIF4F assembly, the phosphorylation of p70 S6 kinase, and
4E-BP1 and increases in protein synthesis were unaffected by
wortmannin (Fig. 3, b-e). These data show that the stimulation
of eIF4F assembly and protein synthesis by TPA occurs
through a pathway which is independent of PI 3-kinase,
whereas PI 3-kinase activity is required for insulin-stimulated
eIF4F assembly and protein synthesis.
PKB Is Activated by Insulin but Not by TPA—Several lines of
evidence suggest that PKB plays an important role in the
regulation of both p70 S6 kinase and 4E-BP1 and that activa-
tion of PKB through phosphorylation by PDK1 and -2 is de-
pendent upon PI 3-kinase (35, 36, 42–46). A number of stimuli
lead to the activation of PKB including insulin (41). There is
also evidence that mTOR is a target for signaling via PKB (42).
As the activation of eIF4F assembly, protein synthesis and
phosphorylation of 4E-BP1 and p70 S6 kinase by TPA did not
require PI 3-kinase, unlike their control by insulin, it was
important to examine how TPA induced these effects. We
therefore investigated whether PKB was activated by TPA and
also in parallel, investigated the activation of PKB by insulin.
Insulin stimulation led to a rapid activation of endogenous
PKB in HEK293 cells (within 5 min, Fig. 4a). Indeed, it has
previously been reported that insulin rapidly activates PKB
expressed from constructs transiently transfected into HEK
293 cells (41). However, TPA did not elicit any detectable
activation of PKB (Fig. 4a). Phosphorylation of PKB at Thr308
and Ser473 is essential for full activation of PKB (41, 47). As an
adjunct to direct measurements of its activity, the phosphoryl-
ation status of PKB following both insulin and TPA treatment
of cells was therefore monitored using a phospho-specific anti-
body against Ser473. Insulin treatment resulted in a rapid
increase in the phosphorylation of PKB at Ser473, which was
sustained throughout the period of the experiment (40 min)
(Fig. 4b). However, TPA treatment of cells did not result in any
detectable phosphorylation at Ser473 (Fig. 4c), consistent with
the absence of a change in activity.
These data reveal a clear difference in the signaling path-
ways through which insulin and TPA regulate protein synthe-
sis, eIF4F assembly, and the phosphorylation of p70 S6 kinase
FIG. 3. TPA does not activate PI 3-kinase. a, in vitro PI 3-kinase
assay of lysates from HEK 293 cells. Cells were serum starved for 16 h
prior to the addition of 100 nM insulin or 1 mM TPA for the time period
indicated: control, unstimulated; insulin, cells stimulated with insulin
for 5 min. Representative of two separate experiments. b-e, HEK 293
cells were serum starved for 16 h, 100 nM wortmannin was added 15
min prior to and after the addition of 100 nM insulin or 1 mM TPA for 45
min. b, analysis of proteins isolated by m7GTP-Sepharose pull-down
separated on a SDS-polyacrylamide gel followed by Western blotting
using antisera against eIF4E, eIF4G1, and 4E-BP1. c, 10 mg of cell
lysates were run on a SDS-polyacrylamide gel followed by Western
blotting using anti-p70 S6 kinase antiserum. d, 20 mg of cell lysates
were run on a SDS-polyacrylamide gel followed by Western blotting
using anti-4E-BP1 antiserum. Phospho-4E-BP1 represents the more
phosphorylated forms of 4E-BP1. Results in b, c, and d are represent-
ative blots from three separate experiments. e, incorporation of [35S]me-
thionine into protein expressed as % of control (n 5 3: 6S.E.).
FIG. 4. Insulin but not TPA activates PKB. a, activation of PKB
assessed by in vitro kinase assay. HEK 293 cells were serum starved for
16 h prior to the addition of either 100 nM insulin for 5 min or 1 mM TPA
for the time periods indicated. PKB was then precipitated from the
lysates for an in vitro PKB assay (see “Experimental Procedures”).
Results are expressed as 32P incorporation into substrate as a % of
control, i.e. unstimulated cells (n 5 3: 6S.E.). b and c, HEK 293 cells
were serum starved for 16 h prior to the addition of either 100 nM
insulin or 1 mM TPA for the time periods indicated. 10 mg of cell lysates
were run on a SDS-polyacrylamide gel and Western blotted using
anti-PKB Ser473 phospho-specific antiserum (upper panel) or as loading
control, anti-PKB antiserum (lower panel). Results are representative
of three separate experiments.
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and 4E-BP1. The effects of insulin require PI 3-kinase (and
may involve activation of PKB) while the effects of TPA are
independent of both.
Role of the MAP Kinase Pathway in TPA and Insulin Stim-
ulated eIF4F Assembly and Protein Synthesis—It has been
shown that phorbol esters activate Erk in many cell types. It
has also been suggested that Erk may play a role in the phos-
phorylation of both p70 S6 kinase (48) and 4E-BP1 (17, 49–51).
We therefore explored the role of Erk in the stimulation by
insulin or TPA of eIF4F assembly, protein synthesis, and the
phosphorylation of 4E-BP1 and p70 S6 kinase.
The activation state of Erk was examined using a phospho-
specific antibody to Erk, which detects the activated forms of
Erk1 and -2. TPA treatment of cells resulted in the phospho-
rylation of Erk (Fig. 5a) concomitant with the phosphorylation
of both p70 S6 kinase and 4E-BP1 observed in Fig. 1. This
suggests that Erk might be involved in the phosphorylation of
p70 S6 kinase and 4E-BP1 in response to TPA. In marked
contrast, insulin treatment did not result in any detectable
phosphorylation of Erk (Fig. 5a).
To study further the role of Erk in TPA-stimulated eIF4F
assembly and protein synthesis, serum-starved cells were pre-
treated with PD098059 (an inhibitor of MEK, the upstream
activator of Erk) (52, 53). As expected, this resulted in a dose-
dependent inhibition of the ability of TPA to induce Erk phos-
phorylation as assessed using the phospho-specific antibody
against Erk (Fig. 6a). The addition of PD098059 also resulted
in a dose-dependent inhibition of TPA-stimulated eIF4F as-
sembly, whereas PD098059, even at higher concentrations,
only had a partial effect on insulin-stimulated eIF4F assembly
(Fig. 6b). Indeed, in many experiments, 50 mM PD098059 had
no effect on insulin-activated eIF4F assembly (results not
shown). PD098059 also caused the dose-dependent inhibition
of the phosphorylation of both 4E-BP1 and p70 S6 kinase in
response to TPA (Fig. 6c). It also inhibited the insulin-induced
phosphorylation of p70 S6 kinase and (partially) of 4E-BP1,
even though phosphorylation of Erk was not observed upon
insulin treatment (Figs. 5 and 6). Inhibition by PD098059 of
insulin-stimulated phosphorylation of p70 S6 kinase and 4E-
BP1 has previously been reported (see “Discussion”) (50).
50 mM PD098059 severely inhibited the rates of basal, TPA-
and insulin-stimulated protein synthesis (Fig. 6d). This does
not appear to be related to the extent of eIF4F assembly (Fig.
6b), since insulin was still able to promote eIF4F assembly in
the presence of PD098059. In order to confirm that these effects
were through the inhibition of MEK, these experiments were
repeated using a structurally unrelated inhibitor of MEK,
U0126 (54). The effects of this compound on TPA or insulin
stimulated phosphorylation of Erk1/2, 4E-BP1, and p70 S6
kinase and eIF4F assembly (Fig. 7, a and b) were very similar
to those observed using PD098059 (Fig. 6). This therefore
strongly suggests that the effects of PD098059 are due to its
ability to inhibit MEK and thus Erk activation.
These results provide strong evidence that the MAP kinase
pathway (specifically MEK) plays an important role in the
stimulation of eIF4F assembly and the phosphorylation of p70
S6 kinase and 4E-BP1 induced by TPA. They also suggest that
this pathway plays a role in maintaining basal translation
rates.
Role of eIF4E Phosphorylation in Basal, TPA, and Insulin-
stimulated eIF4F Assembly and Protein Synthesis—It has been
suggested that phosphorylation of eIF4E may play an impor-
tant role in the regulation of both protein synthesis and eIF4F
assembly (8, 9, 10). Mnk1, the kinase believed to phosphorylate
eIF4E in vivo, lies downstream of Erk and p38 MAP kinase (12,
13, 15), and provides the only established link between Erk
signaling and the translational machinery. Insulin treatment
did not cause phosphorylation of Erk suggesting that increased
eIF4E phosphorylation may not be an essential element in the
stimulation of eIF4F assembly and protein synthesis by insu-
lin. The effect of insulin or TPA treatment on the phosphoryl-
ation of eIF4E was therefore investigated using two different
FIG. 5. TPA, but not insulin, stimulates the phosphorylation of
Erk1 and -2. HEK 293 cells were serum starved for 16 h prior to the
addition of either 100 nM insulin or 1 mM TPA for the time periods
indicated. Western blot analysis of proteins separated by SDS-poly-
acrylamide gel using: a, phospho-specific antibody against Erk1 and -2;
and b, anti-Erk2 antibody as loading control. These results are repre-
sentative of three experiments.
FIG. 6. Effect of PD098059 on eIF4F assembly and protein syn-
thesis. HEK 293 cells were serum starved for 16 h. The cells were then
preincubated in either 25 or 50 mM PD098059 for 45 min before addition
of either 100 nM insulin or 1 mM TPA for an additional 45 min. a,
Western blot analysis, using a phospho-specific antibody against Erk1
and -2. b, analysis of proteins isolated by m7GTP-Sepharose pull-down
separated on a SDS-polyacrylamide gel followed by Western blotting
using antisera against eIF4E, eIF4G1, and 4E-BP1. c, Western blot
analysis using antibodies against either p70 S6 kinase or 4E-BP1.
Phospho-4E-BP1 represents the more phosphorylated forms of 4E-BP1.
d, incorporation of [35S]methionine into protein expressed as percent-
age of control (n 5 5: 6S.E.). All these results are representative of at
least three separate experiments, except where stated.
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but complementary techniques, isoelectric focusing and in vivo
radiolabeling (Fig. 8a). TPA treatment resulted in a large in-
crease in the level of phosphorylation of eIF4E and this effect
was inhibited by PD098059, whereas insulin stimulation did
not alter the levels of phosphorylation of eIF4E (Fig. 8a, i and
ii) (phosphate starvation had no significant effect on the rate of
protein synthesis, results not shown). This demonstrates that
increased phosphorylation of eIF4E is not required for the
stimulation of eIF4F assembly and protein synthesis by insulin
in HEK 293 cells. However, as discussed above, inhibitors of
MEK do inhibit TPA-stimulated eIF4F assembly and protein
synthesis (Figs. 6 and 7) and this could be through the inhibi-
tion of eIF4E phosphorylation. It was also possible that the
observed inhibition of both basal and insulin-stimulated pro-
tein synthesis by the MEK inhibitors was a consequence of the
inhibition of basal eIF4E phosphorylation. eIF4E is indeed
phosphorylated (albeit at a low level) in serum-starved HEK
293 cells (Fig. 8, a and b) and in other cell types (6, 13).
However, PD098059 did not affect the phosphorylation state of
eIF4E in untreated cells (Fig. 8b) indicating that inhibition by
PD098059 of basal rates of translation (Fig. 6) is not due to
decreased eIF4E phosphorylation but rather to the inhibition of
other signals emanating from MEK. However, the inhibition by
PD098059 and U0126 of TPA-stimulated eIF4F assembly and
protein synthesis observed in Figs. 6 and 7 might be related to
inhibition of TPA-stimulated eIF4E phosphorylation (Fig. 8a).
To explore this possibility, HEK 293 cells were transiently
transfected with constructs expressing a constitutively active
form of Mnk1 (Mnk1 T322D) (15). Controls were also per-
formed in which cells were transfected with a plasmid express-
ing green fluorescent protein (GFP). Transfection efficiencies of
over 90% were routinely obtained. Transient transfection of
HEK 293 cells with Mnk1 T332D resulted in over 95% phos-
phorylation of eIF4E in serum-starved, insulin- or TPA-treated
cells (Fig. 8b). As expected, in these cells, the phosphorylation
state of eIF4E was unaffected by the addition of PD098059.
However, in the cells expressing Mnk1 T322D, PD098059 still
inhibited TPA-stimulated eIF4F assembly (Fig. 8c) and protein
synthesis (Fig. 8d) as well as the basal rate of protein synthesis
(Fig. 8d), effects similar to those seen in non-transfected cells
(Fig. 6) (no difference in the effect of the inhibitor or activators
were seen on eIF4F assembly, between the Mnk1 T332D trans-
fected cells and controls, i.e. untransfected or GFP transfected
cells, data not shown). These results indicate that the inhibi-
tion of TPA stimulated eIF4F assembly and protein synthesis
caused by PD098059 is not primarily due to inhibition of eIF4E
phosphorylation but through some other mechanism, presum-
ably through another target of MEK-dependent signaling. In-
terestingly, markedly enhancing the phosphorylation of eIF4E
(to 95%) by expressing constitutively active Mnk1 did not in-
crease basal or insulin-/TPA-stimulated eIF4F assembly or
protein synthesis (Fig. 8, c and d). Thus, elevated levels of
eIF4E phosphorylation are themselves not sufficient to en-
hance either eIF4F assembly or protein synthesis.
DISCUSSION
In this report, we demonstrate that treatment of HEK 293
cells with TPA or insulin leads to increases in both eIF4F
assembly and protein synthesis. TPA or insulin treatment also
led to the phosphorylation of 4E-BP1 and p70 S6 kinase, two
proteins that are important in the regulation of protein syn-
thesis. However, the signaling pathways by which the stimuli
elicit these effects are distinct as TPA stimulation occurs via a
mechanism which does not involve the activation of PI 3-kinase
or PKB whereas insulin stimulation requires PI 3-kinase and
may involve the activation of PKB. Stimulation of eIF4F as-
sembly, protein synthesis, and the phosphorylation of 4E-BP1
and p70 S6 kinase by both agents is inhibited by rapamycin.
TPA activation of MEK appears to be important in increases in
protein synthesis, eIF4F assembly, and the phosphorylation of
p70 S6 kinase and 4E-BP1. The data also suggest that MEK
plays an important role in basal and insulin-stimulated protein
synthesis. Insulin does not stimulate eIF4E phosphorylation
but nevertheless increases eIF4F assembly and protein synthe-
sis. These results indicate that increased eIF4E phosphoryla-
tion is not required for eIF4F assembly or the activation of
general protein synthesis. It should be noted that insulin at the
concentrations used in this report (1027 M), can activate insulin
receptors and those of insulin-like growth factor-1 (55).
Phorbol esters are believed to mediate their effects through
the activation of the diacylglycerol-dependent conventional
PKCs (cPKCs; a, b1, b2, and g) and the novel PKCs (nPKCs; d,
e, h, u, and m) (37) and can activate PI 3-kinase in a number of
cell types, including Swiss 3T3 cells (56), 3T3-L1 adipocytes
(57, 58), and JB6 cells (59). Interestingly, however, in this
report, we do not detect any activation of PI 3-kinase or of a
downstream effector, PKB. The role of PKB in the activation of
p70 S6 kinase and the phosphorylation of 4E-BP1 has been the
subject of several studies. Evidence has mainly relied on the
overexpression of PKB or mutants of PKB within cells (27, 36,
42, 44, 60). Expression of constitutively active mutants of PKB
results in the activation of p70 S6 kinase and the phosphoryl-
ation of 4E-BP1 (44). However, recent evidence suggests that
PKB may not play a critical role in p70 S6 kinase activation,
but does play an important role in the phosphorylation of
4E-BP1 (46). Here we provide evidence that the activation of
PKB is not an essential requirement for the phosphorylation of
either p70 S6 kinase or 4E-BP1, at least upon stimulation with
phorbol ester. Therefore, TPA stimulates the phosphorylation
of p70 S6 kinase and 4E-BP1, eIF4F assembly, and protein
synthesis through a mechanism which is independent of PI
3-kinase and PKB, presumably involving the activation of one
FIG. 7. Effect of U0126 on eIF4F assembly. HEK 293 cells were
serum starved for 16 h. The cells were then preincubated in either 20 or
50 mM U0126 for 45 min before addition of either 100 nM insulin or 1 mM
TPA for a further 45 min. a, analysis of proteins isolated by m7GTP-
Sepharose pull-down separated on a SDS-polyacrylamide gel followed
by Western blotting using antisera against eIF4E, eIF4G1, and 4E-
BP1. b, Western blot analysis using antibodies against either phospho-
Erk1 and -2, p70 S6 kinase, or 4E-BP1. Phospho-4E-BP1 represents the
more phosphorylated forms of 4E-BP1. All these results are represent-
ative of three separate experiments.
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or more members of the cPKC or nPKC families. Consistent
with our data, treatment of interleukin 2-responsive lymphoid
cells with phorbol ester also leads to the activation of p70 S6
kinase via a rapamycin-sensitive, wortmannin-insensitive
pathway (61). These data imply the existence of an alternative
pathway leading to the activation of p70 S6 kinase. However,
the links between PKC and the regulation of p70 S6 kinase and
4E-BP1 remain to be established.
It has been demonstrated that both eIF4F assembly and
protein synthesis can be inhibited by rapamycin probably
through inhibition of the phosphorylation of 4E-BP1 (18–20).
Rapamycin inhibited both insulin- and TPA-induced 4E-BP1
phosphorylation and also inhibited eIF4F assembly, evidence
of the important role 4E-BP1 phosphorylation plays in regulat-
ing both TPA and insulin-stimulated eIF4F assembly and
translation. These data also indicate that TPA and insulin
share commonality in signaling through mTOR and that there-
fore the signaling pathways activated by these stimuli con-
verge, even though their upstream signaling events are
distinct.
Activation of Erk in response to phorbol esters is believed to
be mediated by PKC through the activation of Raf (c-Raf1), an
upstream activator of MEK (62). The activation of Erk by TPA
and its inhibition by inhibitors of MEK correlated well with
changes in protein synthesis, eIF4F assembly, p70 S6 kinase,
and 4E-BP1 phosphorylation, evidence that signaling through
Erk may provide an important input into these events. Indeed,
the MEK inhibitors had a much greater inhibitory effect on
TPA- than insulin-induced eIF4F assembly and the phospho-
rylation of p70 S6 kinase and 4E-BP1. However, the role of Erk
in the stimulation of translation by TPA is difficult to assess
given the strong inhibitory effect of PD098059 on protein syn-
thesis in untreated cells.
In many cell types previously studied insulin treatment re-
sults in the activation of Erk. However, in HEK 293 cells, Erk
is not activated by insulin and therefore Erk activation cannot
play a role in insulin-stimulated protein synthesis or eIF4F
assembly. Surprisingly, pretreatment of cells with inhibitors of
MEK, PD098059, and the structurally unrelated compound
U0126, resulted in an inhibition of insulin-stimulated protein
synthesis as well as basal protein synthesis. This implies that
a basal input from MEK or a kinase downstream of MEK is
required for general protein synthesis. However, this is not due
to the inhibition of the basal level of eIF4E phosphorylation as
PD098059 had no effect on basal eIF4E phosphorylation and
inhibition by PD098059 was not relieved by the overexpression
of constitutively active Mnk1. The insulin induced phosphoryl-
ation of 4E-BP1 and p70 S6 kinase was also partially inhibited
by the MEK inhibitors. The inhibition by PD098059 of insulin-
stimulated p70 S6 kinase and 4E-BP1 phosphorylation has
previously been reported in Chinese hamster ovary cells (50)
but in these cells insulin does activate Erk. However, those
authors show that there was not a clear correlation between
inhibition of Erk activation by PD098059 and the inhibition of
4E-BP1 and p70 S6 kinase phosphorylation. MAP kinase-like
kinase(s) may play an important role in the phosphorylation of
p70 S6 kinase as a number of proline-rich phosphorylation sites
have been identified within the C-terminal pseudosubstrate
domain of p70 S6 kinase (48). It has also been suggested that
Erk/Erk-activated kinases may be involved in the phosphoryl-
ation of 4E-BP1 (17, 49, 50). It is therefore possible that a low
basal activity of MEK is required for both protein synthesis and
the basal phosphorylation of p70 S6 kinase and 4E-BP1 which
accounts for their sensitivity to PD098059.
It has been suggested that eIF4E phosphorylation may also
play an important role in eIF4F assembly and general protein
FIG. 8. Role of eIF4E phosphorylation in eIF4F assembly and translation. a, HEK 293 cells were serum starved for 16 h (for in vitro
labeling cells were additionally starved of phosphate). Where indicated the cells were pretreated with 50 mM PD098059 for 45 min prior to the
addition of 100 nM insulin or 1 mM TPA. (i) Proteins isolated by m7GTP-Sepharose pull-down were separated on an isoelectric focusing gel followed
by Western blot analysis using anti-eIF4E antiserum. Representative blot from three experiments. (ii) 32P in vivo labeled proteins were isolated
by m7GTP-Sepharose pull-down and then separated by SDS-polyacrylamide gel. Radiolabeled eIF4E was visualized by autoradiography. b-d, HEK
293 cells were either transiently transfected with constructs expressing constitutively active Mnk1 T332D or GFP for 24 h before being serum
starved for 16 h. Where indicated the cells were pretreated with 50 mM PD098059 for 45 min prior to the addition of 100 nM insulin or 1 mM TPA
for an additional 45 min. b, analysis of proteins isolated by m7GTP-Sepharose pull-down separated on an isoelectric focusing gel followed by
Western blot analysis using anti-eIF4E antiserum (GFP, serum starved cells transfected with GFP). This experiment was repeated three times.
c, analysis of proteins from Mnk1 T332D-transfected cells isolated by m7GTP-Sepharose pull-down separated on SDS-polyacrylamide gel followed
by Western blotting using antisera against eIF4E, eIF4G1, and 4E-BP1. (Control, untreated cells). Representative results from three separate
experiments. d, incorporation of [35S]methionine into protein expressed as percentage of control (n 5 3: 6S.E.). In all cases, differences in the rates
of protein synthesis between control cells and cells transfected with Mnk1 T332D proved statistically insignificant as judged using Student’s t test
(p 5 0.05).
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synthesis (8, 9). Since insulin treatment of HEK293 cells re-
sults in no detectable phosphorylation of Erk (an upstream
kinase of Mnk1; an eIF4E kinase) or increase in eIF4E phos-
phorylation, stimulation of eIF4E phosphorylation is clearly
not a critical requirement for eIF4F assembly and the activa-
tion of general protein synthesis in response to insulin. How-
ever, eIF4E phosphorylation may play other roles in the up-
regulation of the translation of specific transcripts with highly
structured 59-untranslated regions (63, 64). Interestingly, in-
creased phosphorylation of eIF4E by Mnk1 T332D did not
affect basal, insulin-, or TPA-stimulated eIF4F assembly or
rates of general protein synthesis. This indicates that eIF4E
phosphorylation is not sufficient to increase eIF4F assembly or
general protein synthesis.
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